GO:0000724 double-strand break repair via homologous recombination: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0000724 describes the error-free repair of a DNA double-strand break using a homologous DNA template, resulting in exchange of genetic material between the broken and intact molecules.
• The process is initiated by 5'-to-3' end resection, which commits the break to homologous recombination rather than non-homologous end joining.
• RAD51 is the central recombinase that forms a nucleoprotein filament on single-stranded DNA and catalyzes homology search and strand invasion.
• Homologous recombination repair deficiency (HRD) is a clinically actionable phenotype in breast, ovarian, pancreatic and prostate cancers and predicts PARP inhibitor response.
• RAD51 foci formation is a functional biomarker of homologous recombination repair proficiency and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential to dissect the causal role of homologous recombination genes in disease and therapy response.
Description
Double-strand break repair via homologous recombination (GO:0000724) is a biological process that repairs DNA double-strand breaks (DSBs) with high fidelity by using a homologous DNA sequence as a template. The QuickGO definition states that the broken DNA molecule searches for a homologous region in an intact chromosome to serve as the template for DNA synthesis, restoring two intact DNA molecules and resulting in reciprocal or nonreciprocal exchange of genetic material. This process is synonymous with homology-directed repair (HDR), homologous recombinational repair (HRR), and Rad51-dependent recombinational repair. Homologous recombination repair is essential for genome stability, replication fork restart, and the maintenance of telomeres, and its dysfunction leads to genomic instability and cancer predisposition. The process is tightly regulated by cell cycle stage, with end resection committing the break to homologous recombination in S and G2 phases when a sister chromatid is available. In cancer biology, homologous recombination repair deficiency (HRD) is a clinically validated biomarker that predicts sensitivity to platinum salts and poly(ADP-ribose) polymerase (PARP) inhibitors. Researchers study GO:0000724 using a combination of genetic, biochemical, and cell-based approaches, including RAD51 foci assays, CRISPR knockout and knock-in models, and functional genomics screens. Understanding the molecular players and regulatory layers of homologous recombination repair is critical for developing targeted therapies and overcoming chemoresistance.
double-strand break repair via homologous recombination At A Glance
| GO ID | GO:0000724 |
|---|---|
| GO term | double-strand break repair via homologous recombination |
| Ontology | biological_process |
| Synonym | HDR, homologous recombinational repair, homology-directed repair, HRR, Rad51-dependent recombinational repair, Rhp51-dependent recombinational repair |
| Major function | Error-free repair of DNA double-strand breaks using a homologous template, leading to genetic exchange |
| Key recombinase | RAD51 (eukaryotes), Rhp51 (fission yeast), RecA (bacteria) |
| Pathway choice | Committed by 5'-to-3' end resection; active in S/G2 phases |
| Clinical relevance | Homologous recombination repair deficiency (HRD) predicts PARP inhibitor and platinum sensitivity |
| Research methods | RAD51 foci, CRISPR knockout/knock-in, functional genomics screens, biochemical reconstitution |
What Is GO:0000724?
GO:0000724, double-strand break repair via homologous recombination, is the error-free repair of a DNA double-strand break in which the broken DNA molecule is repaired using homologous sequences. A strand in the broken DNA searches for a homologous region in an intact chromosome to serve as the template for DNA synthesis. The restoration of two intact DNA molecules results in the exchange, reciprocal or nonreciprocal, of genetic material between the intact DNA molecule and the broken DNA molecule.
Why Is double-strand break repair via homologous recombination Important in Cell Biology?
GO:0000724 is fundamentally important because it is the primary error-free mechanism for repairing DNA double-strand breaks, which are the most cytotoxic form of DNA damage. Loss of homologous recombination repair leads to genomic instability, a hallmark of cancer, and germline mutations in homologous recombination genes such as BRCA1 and BRCA2 cause hereditary breast and ovarian cancer syndromes. The process is also a major determinant of response to DNA-damaging chemotherapy and PARP inhibitors, making it a central focus of precision oncology.
• Maintains genome stability by error-free repair of DNA double-strand breaks.
• Deficiency causes genomic instability and predisposes to hereditary breast, ovarian, pancreatic and prostate cancers.
• Predicts sensitivity to PARP inhibitors and platinum-based chemotherapy.
• RAD51 foci formation serves as a functional biomarker of homologous recombination repair proficiency.
• Required for replication fork restart and recovery from replication stress.
• Protects telomeres through shelterin-mediated regulation.
• Coupled to transcription and transcription-coupled DNA repair.
• Regulated by post-translational modifications such as lactylation of BLM.
• Plant-specific modules for homologous recombination repair exist, highlighting evolutionary conservation.
• Target for CRISPR-based functional screens to identify novel homologous recombination factors.
What Happens During double-strand break repair via homologous recombination?
Initiation and end resection
In simple terms: The broken DNA ends are chewed back to create single-stranded DNA tails, which is the first committed step.
Double-strand break repair via homologous recombination begins with 5'-to-3' end resection, in which the MRN complex (MRE11-RAD50-NBS1) and CtIP initiate short-range resection, followed by EXO1 and BLM/DNA2 for long-range resection. This generates 3' single-stranded DNA (ssDNA) overhangs that are bound by replication protein A (RPA). End resection is the key commitment step that channels the break into homologous recombination rather than non-homologous end joining.
RAD51 filament formation and homology search
In simple terms: RAD51 coats the single-stranded DNA and searches for a matching sequence in the intact chromosome.
RPA is replaced by RAD51, mediated by BRCA2 and other mediators, forming a helical nucleoprotein filament on the ssDNA. The RAD51-ssDNA filament performs homology search and strand invasion into the intact sister chromatid or homologous chromosome, forming a displacement loop (D-loop). This step is the defining feature of Rad51-dependent recombinational repair.
DNA synthesis and second-end capture
In simple terms: The missing DNA is copied using the intact template, and the second broken end is captured.
Following strand invasion, the 3' end of the invading strand primes DNA synthesis using the homologous template. The second end of the break is captured, leading to the formation of a double Holliday junction or an alternative intermediate. DNA synthesis restores the genetic information lost at the break site.
Resolution and dissolution
In simple terms: The recombination intermediates are cut or dissolved to restore two intact DNA molecules.
Holliday junctions are resolved by structure-specific nucleases or dissolved by the BLM-TOPOIIIalpha-RMI1-RMI2 complex, resulting in either crossover or non-crossover products. The outcome is the restoration of two intact DNA molecules with reciprocal or nonreciprocal exchange of genetic material. Resolution must be tightly regulated to avoid loss of heterozygosity and genome rearrangements.
Regulation by cell cycle and post-translational modifications
In simple terms: The cell only uses this repair pathway when a template is available, and chemical tags on proteins control the process.
Homologous recombination repair is restricted to S and G2 phases when a sister chromatid is available, regulated by cyclin-dependent kinases and CDK-dependent phosphorylation of resection factors. Post-translational modifications, including lactylation of BLM, modulate homologous recombination repair efficiency and chemoresistance. Transcription-coupled DNA double-strand break repair also influences pathway choice and repair kinetics.
Key Genes Involved in GO:0000724 double-strand break repair via homologous recombination
The following genes and proteins are core components or regulators of double-strand break repair via homologous recombination (GO:0000724), based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RAD51 | Central recombinase forming nucleoprotein filament on ssDNA | Functional biomarker via RAD51 foci; target for inhibitor development |
| BRCA1 | Mediates end resection and RAD51 loading; tumor suppressor | Germline mutations cause hereditary breast/ovarian cancer; HRD biomarker |
| BRCA2 | Mediates RAD51 loading onto ssDNA; tumor suppressor | Germline mutations cause hereditary breast/ovarian cancer; PARP inhibitor sensitivity |
| PALB2 | BRCA2 partner and RAD51 mediator | Germline mutations associated with breast and pancreatic cancer |
| RAD51C | RAD51 paralog; facilitates filament formation | Germline mutations associated with ovarian cancer |
| RAD51D | RAD51 paralog; facilitates filament formation | Germline mutations associated with ovarian cancer |
| MRE11 | MRN complex; initiates end resection | Mutations cause ataxia-telangiectasia-like disorder |
| RAD50 | MRN complex; DNA binding and tethering | Mutations cause Nijmegen breakage syndrome-like disorder |
| NBS1 (NBN) | MRN complex; recruits ATM and resection factors | Mutations cause Nijmegen breakage syndrome |
| CtIP (RBBP8) | Promotes end resection with MRN | Regulates pathway choice; cancer relevance |
| EXO1 | Long-range end resection nuclease | Modulates homologous recombination efficiency |
| BLM | RecQ helicase; dissolves Holliday junctions | Mutations cause Bloom syndrome; lactylation regulates HR |
| ATM | DNA damage sensor kinase; activates checkpoint | Mutations cause ataxia-telangiectasia |
| ATR | Replication stress sensor kinase | Regulates homologous recombination under replication stress |
| RPA | ssDNA-binding protein; removed by RAD51 | Essential for resection and filament formation |
| POLD1 | DNA polymerase delta; synthesis during HR | Replication and repair factor |
| RAD52 | Single-strand annealing and HR backup | Alternative HR pathway; cancer target |
How Is double-strand break repair via homologous recombination Regulated?
Homologous recombination repair is regulated at multiple levels. Cell cycle-dependent CDK phosphorylation controls end resection and restricts homologous recombination to S/G2 phases. The ATM and ATR kinases coordinate the DNA damage response and checkpoint activation, influencing repair pathway choice. Post-translational modifications such as ubiquitination, SUMOylation, and lactylation modulate the stability and activity of homologous recombination factors; for example, AARS1-mediated BLM lactylation promotes homologous recombination repair and chemoresistance. Transcription-coupled DNA double-strand break repair also intersects with homologous recombination, linking RNA polymerase II stalling to repair factor recruitment. In plants, a plant-specific module regulates homologous recombination repair, indicating evolutionary diversification.
double-strand break repair via homologous recombination and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BRCA1 | Hereditary breast and ovarian cancer; HRD | BRCA1 knockout and point-mutation cell lines; RAD51 foci assay |
| BRCA2 | Hereditary breast and ovarian cancer; PARP inhibitor sensitivity | BRCA2 knockout and knock-in models; drug sensitivity screens |
| BLM | Bloom syndrome; chemoresistance via lactylation | BLM knockout and lactylation-site point mutants; irinotecan combination |
| NBS1 (NBN) | Nijmegen breakage syndrome | NBS1 knockout and point-mutation models; DNA damage sensitivity |
| RAD51 | HR proficiency biomarker; cancer therapy response | RAD51 overexpression and knockout; RAD51 foci imaging |
Hereditary breast and ovarian cancer
Germline mutations in BRCA1, BRCA2, PALB2, RAD51C, and RAD51D cause homologous recombination repair deficiency and confer high lifetime risk of breast and ovarian cancer. Tumors with HRD are sensitive to PARP inhibitors and platinum-based chemotherapy, and RAD51 foci formation is used as a functional biomarker to assess HR proficiency and PARP inhibitor resistance.
Therapy resistance and chemoresistance
Restoration of homologous recombination repair, through secondary mutations in BRCA1/BRCA2 or upregulation of HR factors, is a major mechanism of acquired resistance to PARP inhibitors and platinum drugs. BLM lactylation mediated by AARS1 enhances homologous recombination repair and contributes to chemoresistance to anthracyclines, which can be targeted by irinotecan.
Genomic instability syndromes
Biallelic mutations in homologous recombination genes cause genomic instability syndromes, including Bloom syndrome (BLM), Nijmegen breakage syndrome (NBS1), and ataxia-telangiectasia-like disorder (MRE11). These disorders highlight the essential role of homologous recombination in maintaining genome stability and preventing cancer predisposition.
Telomere maintenance and aging
Homologous recombination contributes to telomere maintenance, particularly in alternative lengthening of telomeres (ALT) pathways, and shelterin-mediated telomere protection regulates recombination at chromosome ends. Dysregulation of telomeric homologous recombination is linked to aging and cancer.
From double-strand break repair via homologous recombination-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for homologous recombination repair? | CRISPR knockout cell line followed by RAD51 foci and survival assays |
| Does a specific point mutation affect HR function? | CRISPR point-mutation knock-in of the endogenous locus |
| Does a disease-associated variant impair HR? | Knock-in of the variant allele and functional HR assays |
| Where and when is the protein expressed during HR? | Tagged knock-in (e.g., GFP, HA) for imaging and immunoprecipitation |
| Does overexpression of the gene drive chemoresistance? | CRISPR overexpression (e.g., CRISPRa) or lentiviral overexpression |
| Which genes modulate HR sensitivity to drugs? | Genome-wide CRISPR knockout library screening |
How to Study the double-strand break repair via homologous recombination Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RAD51 foci immunofluorescence | Functional HR proficiency | HRD biomarker in cancer and drug response |
| CRISPR knockout | Loss-of-function phenotype | Causal gene validation in HR |
| CRISPR point-mutation knock-in | Effect of specific variants | Disease variant functional analysis |
| CRISPR overexpression (CRISPRa) | Gain-of-function phenotype | Chemoresistance modeling |
| Genome-wide CRISPR screen | Genes modulating HR or drug sensitivity | Discovery of novel HR factors |
| Biochemical reconstitution | Mechanistic steps of HR | Filament formation and strand invasion |
| Comet assay / gamma-H2AX | DNA damage and repair kinetics | HR pathway choice and efficiency |
| Proteomics / immunoprecipitation | Protein interactions and modifications | HR complex composition and regulation |
RAD51 foci assay
RAD51 foci formation is a functional biomarker of homologous recombination repair proficiency. Cells are treated with DNA-damaging agents, fixed, and stained for RAD51 and a nuclear marker; foci-positive nuclei indicate active HR. This assay is used clinically to assess HRD and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
CRISPR knockout and knock-in models
CRISPR-Cas9 knockout of homologous recombination genes, such as BRCA1, BRCA2, or RAD51, followed by DNA damage sensitivity and RAD51 foci assays, is a standard approach to establish causal roles. Point-mutation knock-in of disease-associated variants allows functional assessment of specific alleles.
Functional genomics screens
Genome-wide CRISPR knockout or activation screens can identify novel homologous recombination factors and modifiers of PARP inhibitor or chemotherapy sensitivity. These screens are powerful for discovering synthetic lethal interactions and resistance mechanisms.
Biochemical reconstitution and structural studies
Reconstitution of homologous recombination with purified proteins, including RAD51, RPA, BRCA2, and BLM, allows mechanistic dissection of filament formation, strand invasion, and Holliday junction resolution. Structural studies provide atomic-level insights into recombinase function.
How CRISPR Can Be Used to Study GO:0000724 double-strand break repair via homologous recombination
Knockout
CRISPR knockout of homologous recombination genes such as BRCA1, BRCA2, RAD51, or BLM is used to create isogenic models of HRD. These models are essential for testing PARP inhibitor sensitivity, RAD51 foci formation, and synthetic lethal interactions. Knockout cell lines also serve as controls for rescue experiments with wild-type or mutant alleles.
Point Mutation
CRISPR point-mutation knock-in introduces specific disease-associated or functional variants into the endogenous locus, preserving physiological expression and regulation. This approach is used to dissect the functional impact of missense mutations in BRCA1, BRCA2, or BLM, including lactylation-site mutants that affect HR and chemoresistance.
Knock-in
CRISPR knock-in of tags (e.g., GFP, HA, or degron) into homologous recombination genes enables live-cell imaging, immunoprecipitation, and controlled protein degradation. Tagged knock-in models are valuable for studying the spatiotemporal dynamics of RAD51 filament formation and Holliday junction resolution.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of homologous recombination genes is used to model gain-of-function phenotypes, such as chemoresistance driven by BLM lactylation or RAD51 overexpression. Overexpression models help identify mechanisms of acquired resistance to PARP inhibitors and platinum drugs.
How EDITGENE Supports double-strand break repair via homologous recombination Research
Researchers studying double-strand break repair via homologous recombination-related genes often need to determine whether a candidate gene is causally involved in DNA repair, genome stability, or therapy response. Establishing causality requires precise genetic models that recapitulate loss-of-function, gain-of-function, or specific disease variants in a relevant cellular context.
Contact EDITGENE today to design your custom CRISPR model for double-strand break repair via homologous recombination research.
Frequently Asked Questions About double-strand break repair via homologous recombination
What is double-strand break repair via homologous recombination?
It is the error-free repair of a DNA double-strand break using a homologous DNA template, defined as GO:0000724, resulting in exchange of genetic material between the broken and intact DNA molecules.
What genes are involved in homologous recombination repair?
Key genes include RAD51, BRCA1, BRCA2, PALB2, RAD51C, RAD51D, MRE11, RAD50, NBS1, CtIP, EXO1, BLM, ATM, ATR, RPA, and RAD52.
What is the difference between homologous recombination and non-homologous end joining?
Homologous recombination uses a homologous template for error-free repair and is active in S/G2, while non-homologous end joining directly ligates broken ends and is error-prone; end resection commits the break to homologous recombination.
Why is homologous recombination repair important in cancer?
Deficiency in homologous recombination repair causes genomic instability and predisposes to hereditary breast, ovarian, pancreatic and prostate cancers, and predicts sensitivity to PARP inhibitors and platinum drugs.
What is a RAD51 foci assay?
It is a functional biomarker assay that detects RAD51 nuclear foci after DNA damage, indicating active homologous recombination repair and helping assess PARP inhibitor resistance.
How is homologous recombination repair regulated?
It is regulated by cell cycle-dependent CDK phosphorylation, ATM/ATR signaling, and post-translational modifications such as ubiquitination, SUMOylation, and lactylation of factors like BLM.
What diseases are linked to defective homologous recombination?
Hereditary breast and ovarian cancer, Bloom syndrome, Nijmegen breakage syndrome, ataxia-telangiectasia-like disorder, and certain pancreatic and prostate cancers.
How do CRISPR models help study homologous recombination?
CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models allow causal testing of gene function, disease variants, and drug resistance mechanisms in homologous recombination repair.
What is homologous recombination deficiency (HRD)?
HRD is a cellular state in which homologous recombination repair is impaired, often due to mutations in BRCA1, BRCA2, or other HR genes, leading to genomic instability and therapeutic vulnerability.
Can homologous recombination repair be targeted therapeutically?
Yes, cancers with HRD are targeted with PARP inhibitors and platinum-based chemotherapy, and mechanisms of resistance such as BLM lactylation are being explored as new targets.
Conclusion
Double-strand break repair via homologous recombination (GO:0000724) is a fundamental, error-free DNA repair process that maintains genome stability and influences cancer predisposition, therapy response, and aging. Its core machinery, centered on RAD51 and regulated by BRCA1, BRCA2, and cell cycle-dependent modifications, is a major focus of cancer research and drug development. CRISPR-based models, including knockout, point-mutation knock-in, tagged knock-in, and overexpression, are indispensable for dissecting the causal roles of homologous recombination genes and for identifying new therapeutic targets. Continued research into this pathway will advance precision oncology and our understanding of genome maintenance.
References
- 1. Doig KD et al.. 2023. Homologous Recombination Repair Deficiency: An Overview for Pathologists.. Mod Pathol 36(3):100049 PMID: 36788098
- 2. Symington LS et al.. 2011. Double-strand break end resection and repair pathway choice.. Annu Rev Genet 45:247-71 PMID: 21910633
- 3. de Lange T. 2018. Shelterin-Mediated Telomere Protection.. Annu Rev Genet 52:223-247 PMID: 30208292
- 4. Cruz C et al.. 2018. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.. Ann Oncol 29(5):1203-1210 PMID: 29635390
- 5. Li X et al.. 2025. Irinotecan alleviates chemoresistance to anthracyclines through the inhibition of AARS1-mediated BLM lactylation and homologous recombination repair.. Signal Transduct Target Ther 10(1):214 PMID: 40634292
- 6. Raina VB et al.. 2025. Biochemical Mechanisms of Genetic Recombination and DNA Repair.. Annu Rev Biochem 94(1):161-193 PMID: 40153609
- 7. Guha S et al.. 2022. Transcription-coupled DNA double-strand break repair.. DNA Repair (Amst) 109:103211 PMID: 34883263
- 8. Wang X et al.. 2022. A plant-specific module for homologous recombination repair.. Proc Natl Acad Sci U S A 119(16):e2202970119 PMID: 35412914
